The JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, published by BMC, is a leading open-access journal dedicated to advancing the field of cancer research and oncology. Since its inception in 1982, this esteemed journal has fostered innovation and collaboration in the scientific community, as evidenced by its outstanding impact factor and position in the Q1 quartile for both Cancer Research and Oncology categories in 2023. With a proud commitment to disseminating high-quality research, the journal operates under an open-access model, ensuring that findings are readily accessible to researchers, healthcare professionals, and students worldwide. The journal has established a distinguished reputation, ranking 23rd out of 404 in Medicine oncology and 16th out of 230 in Biochemistry, Genetics, and Molecular Biology (cancer research), showcasing its importance and influence in guiding the future of cancer treatment and research. With the aim of bridging experimental and clinical research, this journal invites submissions that push the boundaries of our understanding of cancer biology and therapy.

Biomarker Research is a leading open access journal published by BMC, dedicated to advancing the field of biomarker discovery and clinical application. Since its inception in 2013, this journal has become a crucial resource for researchers and professionals in biochemistry, clinical biochemistry, and molecular medicine, achieving a prestigious Q1 ranking in each category in 2023. With an E-ISSN of 2050-7771, it maintains a strong reputation for disseminating high-quality research and innovative findings that contribute to the understanding of disease mechanisms and the development of novel diagnostics and therapeutics. The journal is accessible to a global audience, ensuring that vital research is freely available to promote collaboration and accelerate scientific progress. Operating out of the United Kingdom, Biomarker Research plays a significant role in addressing some of the most pressing challenges in medical research, making it an essential resource for academics, clinicians, and industry professionals alike.

Cancer Cell International, published by BMC, is a transformative open-access journal established in 2001, dedicated to advancing the field of oncology and cancer research. With its ISSN number not specified and an E-ISSN of 1475-2867, the journal proudly operates from the United Kingdom, located at CAMPUS, 4 Crinan St, London N1 9XW, England. Renowned for its rigorous peer-review process, Cancer Cell International has made significant strides, securing a Q2 ranking in Cancer Research and Q1 rankings in both Genetics and Oncology as of 2023. It ranks impressively in Scopus, featuring in the top quintile of Genetics (#37/347) and Oncology (#52/404), indicating its importance within the scientific community. The journal's broad scope caters to a diverse array of topics within cancer biology, making it an invaluable resource for researchers, professionals, and students seeking to stay at the forefront of cancer science. With a commitment to disseminating high-quality research, Cancer Cell International invites scholars to explore innovative findings and contribute to the collective effort of combating cancer.

JOURNAL OF IMMUNOTHERAPY, published by Lippincott Williams & Wilkins, is a premier journal dedicated to advancing the field of immunotherapy, a vital aspect of contemporary cancer research and treatment. With an ISSN of 1524-9557 and an E-ISSN of 1537-4513, this esteemed journal has been disseminating cutting-edge research since 1991 and continues to thrive with a convergence of knowledge leading into 2024. Recognized in the top Q2 quartile for fields such as Cancer Research, Immunology, and Allergy, as well as achieving a Q1 ranking in Pharmacology, the journal serves as a critical resource for researchers, clinicians, and students alike. Its robust impact is reflected in its competitive Scopus rankings across various categories, where it holds significant percentile standings. Highly regarded in the academic community for its rigor, the JOURNAL OF IMMUNOTHERAPY aims to provide a platform for innovative ideas, clinical findings, and experimental research that propels the science of immunotherapy forward. Although it does not offer open access, the journal ensures that its contents remain accessible and impactful for professionals in the field, fostering collaboration and knowledge exchange in an era where immunotherapy holds the promise for breakthroughs in patient care.

Science Immunology, published by the American Association for the Advancement of Science, is a leading journal in the field of immunology, recognized for its significant impact and rigor in advancing our understanding of immune responses and complex diseases. With an impressive impact factor that places it in the Q1 category of both immunology and allergy, as well as miscellaneous medicine, this journal is ranked #7 and #8 in their respective Scopus categories, reflecting its high-quality research output. Since its inception in 2016, Science Immunology has been at the forefront of interdisciplinary immunological research, fostering crucial insights that link immunology with pressing health challenges. The journal is committed to providing open access to its content, ensuring that groundbreaking findings are accessible to a global audience of researchers, professionals, and students. Its anthology not only addresses fundamental immunological mechanisms but also enhances the dialogue on translational applications and therapeutic interventions, solidifying its position as an essential resource within the scientific community.

Targeted Oncology is a premier, peer-reviewed journal published by SPRINGER, focusing on the latest advancements in the field of oncology, specifically targeting the development and application of targeted therapies. Since its inception in 2006, this journal has become an essential resource for researchers, healthcare professionals, and students, providing critical insights into innovative cancer treatments and the pharmacological landscape. Recognized for its impactful contributions, Targeted Oncology holds a distinguished Q1 ranking in both Oncology and Pharmacology categories as of 2023, underscoring its influence and relevance in the scientific community. With an impressive Scopus ranking reflecting its strong citation impact, the journal not only disseminates high-quality research but also facilitates knowledge exchange among oncologists and researchers working towards improving patient outcomes. Although not an Open Access journal, Targeted Oncology is committed to advancing cancer research and therapeutic strategies, making it an invaluable addition to the libraries of any institution dedicated to health and wellness.

GENE THERAPY, published by SpringerNature, is a prestigious academic journal at the forefront of research in the fields of genetics, molecular biology, and molecular medicine. Since its inception in 1994, this journal has evolved into a vital resource for scholars, practitioners, and students, providing cutting-edge insights into gene therapy techniques and innovations. With an impressive impact factor reflecting its significant influence— ranking in the Q1 quartile across multiple categories in 2023—GENE THERAPY offers rigorous peer-reviewed articles that address both basic and applied aspects of gene therapy. The journal is recognized for its role in promoting advancements in therapeutic strategies, thus enhancing understanding of genetic disorders and treatment efficacy. Researchers will find this journal invaluable for publishing their findings, staying updated on the latest breakthroughs, and fostering interdisciplinary collaborations. Engage with the latest in gene therapy by accessing this influential platform, and contribute to a field that holds the potential to transform healthcare outcomes worldwide.

Antibodies is a leading open-access journal published by MDPI since 2012, focusing on the dynamic and rapidly evolving field of immunology and drug discovery. With an E-ISSN of 2073-4468, this esteemed journal aims to provide a platform for the dissemination of high-quality research on all aspects of antibody research, including novel therapeutic strategies, diagnostic applications, and the molecular mechanisms of immune responses. With an impressive portfolio reflecting its standing, Antibodies boasts a 2023 category quartile ranking of Q1 in Drug Discovery and Q2 in both Immunology and Immunology and Allergy. This positions the journal prominently within its field, further underscored by its Scopus rankings that illustrate its influence and relevance, including a rank of #46 out of 157 in Drug Discovery. As a fully open-access journal, Antibodies ensures that groundbreaking research is readily available to a diverse audience, enhancing the collaborative efforts in the scientific community. The journal's headquarters in beautiful Basel, Switzerland, is a testament to its commitment to maintaining high standards of academic excellence while fostering innovation and knowledge exchange among researchers, professionals, and students worldwide.

Cancer and Metastasis Reviews, published by Springer, is a leading journal in the field of oncology and cancer research. With an impressive impact factor placing it in the Q1 category for both Cancer Research and Oncology as of 2023, this journal is ranked 29th out of 404 in Medicine, Oncology, and 22nd out of 230 in Biochemistry, Genetics, and Molecular Biology, reflecting its significant influence and prestige in the academic community. Established in 1982, the journal covers a wide spectrum of topics related to the mechanisms of cancer progression and metastasis, making it an essential resource for researchers, healthcare professionals, and students dedicated to understanding and tackling cancer. Although the journal does not provide open access options, the impactful research it publishes contributes to advances in therapeutic strategies and enhances the collective knowledge surrounding cancer pathophysiology. With research converging from 1982 to 2024, Cancer and Metastasis Reviews continues to be a vital platform for disseminating high-quality scientific information in the ever-evolving landscape of cancer research.

Trends in Cancer is a leading journal published by CELL PRESS, dedicated to advancing the field of cancer research and oncology. Since its inception in 2015, the journal has rapidly gained a reputation for excellence, securing both Q1 rankings in Cancer Research and Oncology categories for 2023 and boasting impressive Scopus ranks—#13 out of 404 in Medicine Oncology and #9 out of 230 in Biochemistry, Genetics and Molecular Biology, thus placing it in the top 4% of its field. The journal aims to publish high-quality, innovative research that offers new insights into cancer biology and treatment strategies. With a commitment to scholarly rigor and a broad scope that encompasses molecular mechanisms to therapeutic approaches, Trends in Cancer serves as an essential resource for researchers, professionals, and students eager to stay informed about the latest developments in cancer science. Although it is not an open-access journal, its contributions are pivotal in shaping the future of cancer research.